Investigational Drug Information for RIST4721
What is the development status for investigational drug RIST4721?
RIST4721 is an investigational drug.
There have been 6 clinical trials for RIST4721.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 5th 2022.
The most common disease conditions in clinical trials are Psoriasis, Blister, and Hereditary Autoinflammatory Diseases. The leading clinical trial sponsors are Aristea Therapeutics, Inc. and [disabled in preview].
There are twenty-seven US patents protecting this investigational drug and one hundred and thirty-eight international patents.
Summary for RIST4721
| US Patents | 27 |
| International Patents | 138 |
| US Patent Applications | 87 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 2 (2022-01-05) |
| Vendors | 24 |
Recent Clinical Trials for RIST4721
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF) | Aristea Therapeutics, Inc. | Phase 2 |
| A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS) | Aristea Therapeutics, Inc. | Phase 2 |
| A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) | Aristea Therapeutics, Inc. | Phase 2 |
Clinical Trial Summary for RIST4721
Top disease conditions for RIST4721
Top clinical trial sponsors for RIST4721
US Patents for RIST4721
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| RIST4721 | ⤷ Start Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Start Trial |
| RIST4721 | ⤷ Start Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Start Trial |
| RIST4721 | ⤷ Start Trial | CXCR-2 inhibitors for treating crystal arthropathy disorders | Ardea Biociences Inc | ⤷ Start Trial |
| RIST4721 | ⤷ Start Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | Biofocus DPI Ltd , AstraZeneca AB | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for RIST4721
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| RIST4721 | Argentina | AR099177 | 2034-01-24 | ⤷ Start Trial |
| RIST4721 | Australia | AU2015208932 | 2034-01-24 | ⤷ Start Trial |
| RIST4721 | Australia | AU2017200338 | 2034-01-24 | ⤷ Start Trial |
| RIST4721 | Australia | AU2018202956 | 2034-01-24 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
